Active Biotech

August 10, 2012 02:40 ET

Active Biotech AB Interim report January - June 2012

LUND, SWEDEN--(Marketwire - Aug 10, 2012) -

* Laquinimod - application submitted for regulatory approval in the EU resulting in milestone payment of USD 5 M during third quarter 2012 - a Phase III study will be initiated in the US

* TASQ - milestone payment of EUR 10 M received from Ipsen in connection with meeting patient enrolment target for Phase III study - overall survival data from Phase II study presented

* ANYARA - Phase III trial continuing according to plan

* 57-57 - a clinical trial in systemic sclerosis/scleroderma in progress

* ISI - project proceeding as planned

* The organization has been adapted to the company's new direction

* Net sales: SEK 96.6 M (228.8)

* Operating loss: SEK 120.6 M (profit: 70.6)

* Loss after tax: SEK 123.5 M (profit: 77.7)

* Loss per share for the period: SEK 1.79 (earnings: 1.14)


This report is also available at www.activebiotech.com
Fax: +46 (0)46 19 11 00


Active Biotech AB Interim report Jan - June 2012: http://hugin.info/1002/R/1633117/523993.pdf


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1633117]

Contact Information

  • For further information, please contact:

    Tomas Leanderson
    President and CEO
    Tel: +46 (0)46 19 20 95

    Hans Kolam
    CFO
    Tel: +46 (0)46 19 20 44

    Active Biotech AB (Corp. Reg. No. 556223-9227)
    PO Box 724, SE-220 07 Lund
    Tel: +46 (0)46 19 20 00